CATX Perspective Therapeutics, Inc.

In early September 2026, Merck & Co., Inc. deepened its innovation push through multiple investor conferences and a new clinical trial collaboration in which Perspective Therapeutics announced it will test its targeted alpha therapy [212Pb]PSV359 with Merck’s immunotherapy Keytruda in certain FAP-a–expressing lung and colorectal cancers. At the same time, Merck partnered with The Hashgraph Group and PwC Germany on a cocoa traceability pilot that links its M-Trust physical authentication...

Perspective Therapeutics' (CATX) NET program to potentially treat neuroendocrine tumors may be advan

Profound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.